Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia.
Publication/Presentation Date
7-1-2024
Abstract
OBJECTIVES: The objective of this study is to validate a hypothesis that a non-invasive optical imaging assay targeting genomic VPAC receptors on malignant cells shed in voided urine will represent either benign prostatic hyperplasia (BPH) or prostatic cancer (PCa). Risk for BPH in men 50-70 years old is 50-70% and PCa is 17%. BPH and PCa can coexist in 20% of men with BPH. Most commonly practiced methods to diagnose BPH do not distinguish BPH from PCa.
PATIENTS OR MATERIALS AND METHODS: Males with BPH (
RESULTS: Eighty-seven subjects were negative for VPAC expression. Positive VPAC expression was noted in 10 subjects. Patient chart review for clinical data on these 10 VPAC positive subjects showed five had nephrolithiasis, three had renal cysts, one had prostatitis and one was being treated with finasteride. Real-time polymerase chain reaction analysis-VPAC expressions for 7 normal and 12 BPH subjects were 1.31 ± 1.26 and 0.94 ± 0.89, respectively (
CONCLUSION: VPAC assay may contribute extensively for BPH diagnosis and warrant continued investigation.
Volume
5
Issue
7
First Page
675
Last Page
680
ISSN
2688-4526
Published In/Presented At
Thakur, M., Tomar, V. S., Dale, E., Gomella, L. G., Solomides, C., Kolesnikov, O., Keith, S. W., Navarro, H. T., Dahlgren, O., Chaga, M., & Trabulsi, E. J. (2024). Targeting genomic receptors in voided urine for confirmation of benign prostatic hyperplasia. BJUI compass, 5(7), 675–680. https://doi.org/10.1002/bco2.362
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
39022663
Department(s)
Administration and Leadership
Document Type
Article